|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hyponatremia in patients with heart failure显示文摘The present review analyses the mechanisms relating heart failure and hyponatremia,describes the association of hyponatremia with the progress of disease and morbidity/mortality in heart failure patients and presents treatment options focusing on the role of arginine vasopressin(AVP)-receptor antagonists.Hyponatremia is the most common electrolyte disorder in the clinical setting and in hospitalized patients.Patients with hyponatremia may have neurologic symptoms since low sodium concentration produces brain edema,but the rapid correction of hyponatremia is also associated with major neurologic complications.Patients with heart failure often develop hyponatremia owing to the activation of many neurohormonal systems leading to decrease of sodium levels.A large number of clinical studies have associated hyponatremia with increased morbidity and mortality in patients hospitalized for heart failure or outpatients with chronic heart failure.Treatment options for hyponatremia in heart failure,such as water restriction or the use of hypertonic saline with loop diuretics,have limited efficacy.AVP-receptor antagonists increase sodium levels effectively and their use seems promising in patients with hyponatremia.However,the effects of AVP-receptor antagonists on hard outcomes in patients with heart failure and hyponatremia have not been thoroughly examined. | Theodosios D Filippatos Moses S Elisaf | 2013 | World Journal of Cardiology2013，5，9： | 13 |
| 2 | Effects of glucagon-like peptide-1 receptor agonists on renal function显示文摘Glucagon-like peptide-1(GLP-1)receptor agonists result in greater improvements in glycemic control than placebo and promote weight loss with minimal hypoglycemia in patients with type 2 diabetes mellitus.A number of case reports show an association of GLP-1receptor agonists,mainly exenatide,with the development of acute kidney injury.The present review aims to present the available data regarding the effects of GLP-1 receptor agonists on renal function,their use in subjects with chronic renal failure and their possible association with acute kidney injury.Based on the current evidence,exenatide is eliminated by renal mechanisms and should not be given in patients with severe renal impairment or end stage renal disease.Liraglutide is not eliminated by renal or hepatic mechanisms,but it should be used with caution since there are only limited data in patients with renal or hepatic impairment.There is evidence from animal studies that GLP-1 receptor agonists exert protective role in diabetic nephropathy with mechanisms that seem to be independent of their glucose-lowering effect.Additionally,there is evidence that GLP-1 receptor agonists influence water and electrolyte balance.These effects may represent new ways to improve or even prevent diabetic nephropathy. | Theodosios D Filippatos Moses S Elisaf | 2013 | World Journal of Diabetes2013，4，5： | 9 |
| 3 | Role of ezetimibe in non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease (NAFLD) encompasses a histological spectrum ranging from simple steatosis to steatohepatitis,advanced fibrosis and inflammatory changes.Ezetimibe inhibits cholesterol absorption from the intestinal lumen into enterocytes.The molecular target of ezetimibe is the sterol transporter Niemann-Pick C1-like 1 protein (NPC1L1).Human NPC1L1 is abundantly expressed in the liver and may facilitate the hepatic accumulation of cholesterol.Ezetimibe ex-erts beneficial effects on several metabolic variables.Ezetimibe treatment attenuates hepatic steatosis and is beneficial in terms of NAFLD biochemical markers.The combination of ezetimibe with other interventions may also be beneficial in NAFLD patients.Our group inves-tigated the ezetimibe-orlistat combination treatment in overweight and obese patients with hypercholeste-rolemia,with beneficial effects on NAFLD biochemical markers.These results are promising for patients with NAFLD,who usually have increased cardiovascular disease risk and need a multifactorial treatment.How-ever,it should be mentioned that most results are from animal studies and,although modest elevation of liver function tests may raise the suspicion of NAFLD,none of these tests are sensitive to establish the diagnosis of NAFLD with great accuracy. | Theodosios D Filippatos Moses S Elisaf | 2011 | World Journal of Hepatology2011，3，10： | 4 |
| 4 | Thiazide-associated hyponatremia in the elderly: what the clinician needs to know显示文摘导致 Thiazide 的 hyponatremia 是在老个人的减少的钠层次的主要原因之一。这评论关于联系 thiazide 的 hyponatremia 介绍当前的证据。联系 Thiazide 的 hyponatremia 与象收到 thiazides 的大剂量的那些那样的某些风险因素主要在病人被观察,有许多 comorbidity,例如心失败,肝疾病或恶意,并且拿几药,例如 non-steroidal 反煽动性的药,选择血清素重新举起禁止者或 tricyclic 抗抑郁剂。钠集中应该为开发联系 thiazide 的 hyponatremia 与风险因素在病人被监视,临床医生们应该即时与显示减少的钠层次的神经符号在病人测量浆液钠层次。有联系 thiazide 的 hyponatremia 的病人的临床、生物化学的侧面可以是细胞外的体积弄空或不恰当的尿分泌抑制剂荷尔蒙分泌物(SIADH ) 的症候群的。可能的联系 thiazide 的 hyponatremia 的调查由于 thiazides (弄空相关的细胞外的体积或象 SIADH 一样) 包括减少的钠层次的另外的原因和 hyponatremia 的特征的鉴定的排除。治疗应该小心地被监视由于 overcorrection 避免严肃的神经复杂并发症。临床医生们应该阻止与联系利尿剂的 hyponatremia 的历史在病人规定 thiazides 并且应该为开发联系 thiazide 的 hyponatremia 与风险因素在病人比较喜欢 thiazides 的低剂量。 | George Liamis Theodosios D Filippatos Moses S Elisaf | 2016 | Journal of Geriatric Cardiology2016，13，2： | 3 |
| 5 | Combination drug treatment in patients with non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease (NAFLD) includes simple steatosis, a benign condition, and non-alcoholic steatohepatitis, a condition that beyond TG accumulation also includes necroinflammation and fibrosis. An association between NAFLD and cardiovascular disease (CVD) has been recently suggested. NAFLD patients usually have an increased CVD risk profile. NAFLD is also associated with metabolic syndrome (MetS) and is considered as the hepatic component of MetS by some authors. Currently, the only established treatment of NAFLD is gradual weight loss. However, multifactorial treatment of NAFLD risk factors may be needed to reduce the increased CVD risk of NALFD patients. Drug combinations that include antiobesity drugs (such as orlistat and sibutramine) and target CVD risk factors may be a good approach to NAFLD patients. Our group has investigated the orlistat-fenofibrate combination treatment in obese patients with MetS and the orlistatezetimibe and sibutramine-antihypertensive combination treatment in obese patients with hyperlipidaemia with promising results in CVD risk factor reduction and improvement of liver function tests. Small studies give promising results but double-blind, randomized trials examining the effects of such multifactorial treatment in hard CVD endpoints in NAFLD patients are missing. | Theodosios D Filippatos Moses S Elisaf | 2010 | World Journal of Hepatology2010，2，4： | 2 |
| 6 | Segmentation of plane curves 显示文摘 | Theodosios P Horowitz S L | 1974 | IEEE Transactions on Computers1974，23，8： | 1 |
| 7 | The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia显示文摘 | Aris P Agouridis Vasilis Tsimihodimos Theodosios D Filippatos Andromachi A Dimitriou Costantinos C Tellis Moses S Elisaf Dimitri P Mikhailidis Alexandros D Tselepis | 2011 | Expert Opinion on Pharmacotherapy2011，，17： | 1 |
| 8 | High density lipoprotein and cardiovascular diseases显示文摘Several epidemiological studies have clearly shown that low plasma levels of high density lipoprotein cholesterol (HDL-C) represent a cardiovascular disease (CVD) risk factor. However, it is unclear if there is a causal association between HDL-C concentration and CVD. A recent study published in the Lancet, which performed two Mendelian randomization analyses, showed that increased HDL-C levels were not associated with a decreased risk of myocardial infarction. These findings, together with the termination of the niacin-based AIM-HIGH trial and the discontinuation of cholesteryl ester transfer protein inhibitor dalcetrapib, challenge the concept that raising of plasma HDL-C will uniformly translate into reductions in CVD risk. HDL particles exhibit several anti-atherosclerotic properties, such as anti-inflammatory and anti-oxidative activities and cellular cholesterol efflux activity. Furthermore, HDL particles are very heterogeneous in terms of size, structure, composition and metabolism. HDL functionality may be associated more strongly with CVD risk than the traditional HDL-C levels. More research is needed to assess the association of the structure of HDL particle with its functionality and metabolism. | Theodosios D Filippatos Moses S Elisaf | 2013 | World Journal of Cardiology2013，5，7： | 1 |
| 9 | Spectrophotometric determination of trace amounts of vanadium based on its catalytic effect on the reaction of diphenylamine and hydrogen peroxide显示文摘 | THEODOSIOS S S YANNIS M A MAMAS I P | 2000 | Mikrochim Acta2000，135，3： | 1 |
| 10 | PCSK9 and carbohydrate metabolism:A double-edged sword显示文摘Proprotein convertase subtilisin/kexin type 9(PCSK9) plays a paramount role in the degradation of lowdensity lipoprotein(LDL) receptors(LDLR) on the hepatic cells surface and subsequently affects LDL particles catabolism and LDL cholesterol(LDL-c) levels. The anti-PCSK9 monoclonal antibodies lead to substantial decrease of LDL-c concentration. PCSK9(which is also expressed in pancreatic delta-cells) can decrease LDLR and subsequently decrease cholesterol accumulation in pancreatic beta-cells, which impairs glucose metabolism and reduces insulin secretion. Thus, a possible adverse effect of PCSK9 inhibitors on carbohydrate metabolism may be expected by this mechanism, which has been supported by the mendelian studies results. On the other hand, clinical data have suggested a detrimental association of PCSK9 with glucose metabolism. So, the inhibition of PCSK9 may be seen as a double-edged sword regarding carbohydrate metabolism. Completed clinical trials have not shown a detrimental effect of PCSK9 inhibitors on diabetes risk, but their short-term duration does not allow definite conclusions. | Theodosios D Filippatos Sebastian Filippas-Ntekouan Eleni Pappa Thalia Panagiotopoulou Vasilios Tsimihodimos Moses S Elisaf | 2017 | World Journal of Diabetes2017，8，7： | 1 |
| 11 | Buried bumper syndrome:A critical analysis of endoscopic release techniques显示文摘Buried bumper syndrome(BBS)is the situation in which the internal bumper of the gastrostomy tube,due to prolonged compression of the tissues between the external and the internal bumper,migrates from the gastric lumen into the gastric wall or further,into the tract outside the gastric lumen,ending up anywhere between the stomach mucosa and the surface of the skin.This restricts liquid food from entering the stomach,since the internal opening is obstructed by gastric mucosal overgrowth.We performed a comprehensive search of the PubMed literature to retrieve all the case-reports and case-series referring to BBS and its management,after which we focused on the endoscopic techniques for releasing the internal bumper to re-establish the functionality of the tube.From the“push”and the“push and pull T”techniques to the most sophisticated-using high tech instruments,all 10 published techniques have been critically analysed and the pros and cons presented,in an effort to optimize the criteria of choice based on maximum efficacy and safety. | Alexandra Menni Georgios Tzikos George Chatziantoniou Persefoni Gionga Theodosios S Papavramidis Anne Shrewsbury George Stavrou Katerina Kotzampassi | 2023 | World Journal of Gastrointestinal Endoscopy2023，15，2： | 0 |
| 12 | Combination drug treatment in obese diabetic patients显示文摘Drug combinations that include antiobesity drugs(such as orlistat and sibutramine) and target cardiovascular disease(CVD) risk factors may be a good approach to patients with type 2 diabetes and/or metabolic syndrome(MetS).Our group has investigated the orlistat-fenofibrate combination treatment in obese patients with MetS and the orlistat-ezetimibe and the sibutramine-antihypertensive combination treatment in obese patients with hyperlipidaemia with promising results in CVD risk factor reduction.In these studies,the combination treatment significantly improved the lipid and lipoprotein profile,the carbohydrate metabolism parameters and many other variables playing a role in the atherosclerotic process.Small studies give pro m ising results but double-blind,randomized trials examining the effects of such multif actorial treatment in hard CVD endpoints in diabet ic or MetS patients are missing. | Theodosios D Filippatos Moses S Elisaf | 2010 | World Journal of Diabetes2010，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员